Cethromycin: Difference between revisions
Jump to navigation
Jump to search
m Protected "Cethromycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Protected "Cethromycin": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 28: | Line 28: | ||
| routes_of_administration = Oral | | routes_of_administration = Oral | ||
}} | }} | ||
__NOTOC__ | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Cethromycin''' (initially known as '''ABT-773''') is a [[macrolide]] [[antibiotic]] undergoing research for the treatment of [[community acquired pneumonia]] (CAP) and for the prevention of post-exposure inhalational [[anthrax]], and was given an "[[orphan drug]]" status for this indication.<ref>http://www.advancedlifesciences.com/product.php?id=1</ref> Originally discovered and developed by [[Abbott Laboratories|Abbott]], it was acquired by Advanced Life Sciences Inc. for further development. | '''Cethromycin''' (initially known as '''ABT-773''') is a [[macrolide]] [[antibiotic]] undergoing research for the treatment of [[community acquired pneumonia]] (CAP) and for the prevention of post-exposure inhalational [[anthrax]], and was given an "[[orphan drug]]" status for this indication.<ref>http://www.advancedlifesciences.com/product.php?id=1</ref> Originally discovered and developed by [[Abbott Laboratories|Abbott]], it was acquired by Advanced Life Sciences Inc. for further development. | ||
| Line 40: | Line 37: | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist|2}} | ||
{{Macrolides, lincosamides and streptogramins}} | {{Macrolides, lincosamides and streptogramins}} | ||
| Line 46: | Line 43: | ||
[[Category:Macrolide antibiotics]] | [[Category:Macrolide antibiotics]] | ||
[[Category:Quinolines]] | [[Category:Quinolines]] | ||
[[Category:Drug]] | |||
Latest revision as of 18:55, 18 August 2015
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C42H59N3O10 |
| Molar mass | 765.931 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cethromycin (initially known as ABT-773) is a macrolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication.[1] Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.
On April 10, 2008, Advanced Life Sciences announced that, based on a productive meeting with the U.S. Food and Drug Administration (FDA), it plans to submit a New Drug Application (NDA) in the third quarter of 2008 for cethromycin to treat mild-to-moderate community acquired pneumonia.[2]
References
Categories:
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Macrolide antibiotics
- Quinolines
- Drug